Paul Jeng
Stock Analyst at Guggenheim
(2.23)
# 3,098
Out of 4,670 analysts
29
Total ratings
65.4%
Success rate
2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintained: Buy | $10 | $4.01 | +149.38% | 6 | Aug 12, 2026 | |
| CHRS Coherus Oncology | Maintained: Buy | $12 → $10 | $1.42 | +604.23% | 2 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $54 | $39.67 | +36.12% | 8 | Aug 4, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $45 | $10.38 | +333.53% | 2 | Jun 2, 2026 | |
| IMTX Immatics | Maintained: Buy | $19 | $8.93 | +112.77% | 5 | May 12, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $0.5001 | +899.80% | 4 | May 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $36.88 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $3.85 | n/a | 1 | Jul 29, 2020 |
Adagene
Aug 12, 2026
Maintained: Buy
Price Target: $10
Current: $4.01
Upside: +149.38%
Coherus Oncology
Aug 6, 2026
Maintained: Buy
Price Target: $12 → $10
Current: $1.42
Upside: +604.23%
IDEAYA Biosciences
Aug 4, 2026
Maintained: Buy
Price Target: $54
Current: $39.67
Upside: +36.12%
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Maintained: Buy
Price Target: $45
Current: $10.38
Upside: +333.53%
Immatics
May 12, 2026
Maintained: Buy
Price Target: $19
Current: $8.93
Upside: +112.77%
Context Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.5001
Upside: +899.80%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $36.88
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $3.85
Upside: n/a